Thus, the inhibition of EGFR gene amplification and kinase activating mutants or the targeting of a unique EGFR epitope such as EGFRvIII with monoclonal antibodies for the inhibition of NF‐κB as well as tumour angiogenesis and growth may be rational strategies for the development of glioma therapy. Here, NFKB1 is linked to neoplasm.